Last edition
News about "Sobi Advances Tryngolza Expansion"
Sobi Advances Tryngolza Expansion with EMA Validation for sHTG
Sobi has announced that the European Medicines Agency (EMA) has validated its application to expand the indication of Tryngolza (olezarsen) for the treatment of adults with severe hypertriglyceridemia (sHTG), defined by triglyceride levels ≥880 mg/dL (≥10 mmol/L).
Sobi Advances Tryngolza Expansion | 31/03/2026 | By Darshana | 162
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members